An exonuclease-resistant chain-terminating nucleotide analogue targeting the SARS-CoV-2 replicase complex
Description
Nucleotide analogues (NA) are currently employed for treatment of several viral diseases, including COVID-19. NA prodrugs are intracellularly activated to the 5'-triphosphate form. They are incorporated into the viral RNA by the viral polymerase